Welcome, Guest. Please login or register.
December 04, 2020, 05:47:55 am

Login with username, password and session length


Members
Stats
  • Total Posts: 55052
  • Total Topics: 4816
  • Online Today: 55
  • Online Ever: 1314
  • (June 22, 2016, 05:23:42 am)
Users Online
Users: 0
Guests: 38
Total: 38

Welcome

Welcome to the Hep Forums, a round-the-clock discussion area for people who have Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Another Blow to Merck in $2.5 Billion Hep C Patent Suit Against Gilead  (Read 648 times)

0 Members and 1 Guest are viewing this topic.

Offline Hep Editors

  • Member
  • Posts: 772
    • Hep Mag
Merck lost out in yet another round in its attempt to secure $2.54 billion in damages in a patent dispute with Gilead Sciences over the hepatitis C virus (HCV) blockbuster drugs Sovaldi (sofosbuvir) and Harvoni (ledipasvir/sofosbuvir), Reuters reports. A U.S. appeals court upheld a ruling by a federal judge in Delaware that found that the Merck patent in question was invalid.

In 2016, a jury found that Gilead’s Sovaldi and Harvoni infringed upon the patent that Merck secured when it acquired Idenix Pharmaceuticals. The $2.54 billion that the jury concluded Gilead should pay Merck in damages set a U.S. patent case record.

Read more...
https://www.hepmag.com/article/another-blow-merck-25-billion-hep-c-patent-suit-gilead

 


© 2020 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.